Test Code AMLMF Acute Myeloid Leukemia (AML), Specified FISH, Varies
Ordering Guidance
This test is intended for instances when limited acute myeloid leukemia (AML) fluorescence in situ hybridization (FISH) probes are needed based on specific abnormalities or abnormalities identified in the diagnostic sample. If targeted FISH probes are not included with this test order, test processing will be delayed and the test may be canceled and automatically reordered by the laboratory as either AMLAF / Acute Myeloid Leukemia (AML), FISH, Adult, Varies or AMLPF / Acute Myeloid Leukemia (AML), FISH, Pediatric, Varies depending on the age of the patient.
If the entire AML FISH panel is preferred for an adult patient, order AMLAF / Acute Myeloid Leukemia (AML), FISH, Adult, Varies.
If the entire AML FISH panel is preferred for a pediatric patient, order AMLPF / Acute Myeloid Leukemia (AML), FISH, Pediatric, Varies.
At diagnosis, conventional cytogenetic studies (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow) and a complete AML FISH panel (either AMLAF or AMLPF) should be performed.
Minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia (AML) known to have either t(15;17) with PML::RARA fusion, inv(16) or t(16;16) with MYH11::CBFB fusion, t(8;21) with RUNX1T1::RUNX1 fusion, or t(9;22) with BCR::ABL1 fusion should be performed by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and NOT by FISH testing.
It is recommended that MRD monitoring in AML patients be performed by AML-MRD Flow cytometry rather than FISH testing using individual FISH probe sets. This is particularly true for the deletion/monosomy probe sets (5, 7, 17) which have cutoffs that exceed 10% of nuclei.
If this test is ordered and the laboratory is informed that the patient is 30 years of age or younger AND is on a Children's Oncology Group protocol, this test will be canceled and automatically reordered by the laboratory as COGMF / Acute Myeloid Leukemia (AML), Children's Oncology Group Enrollment Testing, FISH, Varies.
For testing paraffin-embedded tissue samples from patients with AML/myeloid sarcoma, order MSTF / Myeloid Sarcoma, FISH, Tissue.
Shipping Instructions
Advise Express Mail or equivalent if not on courier service.
Necessary Information
A list of targeted probes requested for analysis is required. Probes available for this test are listed in the Testing Algorithm section.
A reason for testing and a flow cytometry and/or a bone marrow pathology report are requested with each specimen. The laboratory will not reject testing if this information is not provided; however, appropriate testing and/or interpretation may be compromised or delayed in some instances. If not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Specimen Required
Submit only 1 of the following specimens:
Preferred:
Specimen Type: Bone marrow
Container/Tube:
Preferred: Yellow top (ACD)
Acceptable: Green top (heparin) or lavender top (EDTA)
Specimen Volume: 2 to 3 mL
Collection Instructions:
1. It is preferable to send the first aspirate from the bone marrow collection.
2. Invert several times to mix bone marrow.
3. Send bone marrow in original tube. Do not aliquot.
Acceptable:
Specimen Type: Blood
Container/Tube:
Preferred: Yellow top (ACD)
Acceptable: Green top (heparin) or lavender top (EDTA)
Specimen Volume: 6 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood in original tube. Do not aliquot.
Secondary ID
614202Useful For
Detecting recurrent common chromosome abnormalities seen in patients with acute myeloid leukemia (AML) using a client-specified probe set
An adjunct to chromosome studies in patients with AML
Evaluating specimens in which chromosome studies are unsuccessful
Testing Algorithm
This test includes a charge for the probe application, analysis, and professional interpretation of results for one probe set (2 individual fluorescence in situ hybridization probes). Additional charges will be incurred for all additional probe sets performed.
This is not intended as a panel test and the desired probes must be specified upon order. If the patient is being evaluated for known abnormalities, targeted probes must be listed in the probe request field. Reflex probes can be performed when appropriate only if specified in the order request field.
When specified, any of the following probes will be performed:
t(8;21), RUNX1T1::RUNX1
Reflex: t(3;21)(q26.2;q22) MECOM::RUNX1
t(15;17), PML::RARA
Reflex: 17q21 rearrangement, RARA break-apart
11q23 rearrangement, MLL (KMT2A)
Reflex: t(4;11)(q21;q23), AFF1::MLL
Reflex: t(6;11)(q27;q23), MLLT4(AFDN)::MLL
Reflex: t(9;11)(p22;q23), MLLT3::MLL
Reflex: t(10;11)(p13;q23), MLLT10::MLL
Reflex: t(11;16)(q23;p13.3), MLL::CREBBP
Reflex: t(11;19)(q23;p13.1), MLL::ELL
Reflex: t(11;19)(q23;p13.3), MLL::MLLT1
inv(16) or t(16;16), MYH11::CBFB
Reflex: 16q22 rearrangement, CBFB break-apart
inv(16), GLIS2::CBFA2T3
11p15.4 rearrangement, NUP98 break-apart
Reflex: t(7;11)(p15;p15.4), HOXA9::NUP98
12p13 rearrangement, ETV6 break-apart
Reflex: t(7;12)(q36;p13), MNX1::ETV6
t(6;9), DEK::NUP214
inv(3) or t(3;3), RPN1::MECOM
Reflex: t(1;3)(p36;q21), PRDM16::RPN1
Reflex: t(3;21)(q26.2;q22), MECOM::RUNX1
t(8;16), KAT6A::CREBBP
t(1;22), RBM15::MKL1
-5/5q-, D5S630/EGR1
-7/7q-, D7Z1/ D7S486
17p-, TP53/D17Z1
t(9;22), BCR::ABL1
Reflex: 9q34 rearrangement, ABL1 break-apart
Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.
For more information see:
Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up
Special Instructions
Method Name
Fluorescence In Situ Hybridization (FISH)
Reporting Name
AML, Specified FISHSpecimen Type
VariesSpecimen Minimum Volume
Blood: 2 mL
Bone Marrow: 1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Refrigerated |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Acute myeloid leukemia (AML) is one of the most common adult leukemias, with almost 10,000 new cases diagnosed per year. AML also comprises 15% of pediatric acute leukemia and accounts for the majority of infant (<1 year old) leukemia.
Several recurrent chromosomal abnormalities have been identified in AML with associated clinical significance. The most common chromosome abnormalities associated with AML include t(8;21), t(15;17), inv(16) or t(16;16), and abnormalities of the MLL (KMT2A) gene at 11q23. The most common genes juxtaposed with MLL through translocation events in AML include MLLT3- t(9;11), MLLT4- t(6;11), MLLT10- t(10;11), and ELL- t(11;19p13.1).
Other recurrent chromosome abnormalities associated with AML include inv(3) or t(3;3), t(6;9) and t(9;22). In addition, AML can also evolve from myelodysplasia (MDS). Thus, the common chromosome abnormalities associated with MDS can also be identified in AML, which include: inv(3) or t(3;3), -5/5q-, -7/7q-, and 17p. Overall, the recurrent chromosome abnormalities identified in patients with AML are observed in approximately 60% of diagnostic AML cases.
Conventional chromosome analysis is the gold standard for identification of the common, recurrent chromosome abnormalities in AML. However, some of the subtle rearrangements can be missed by karyotype, including inv(16) or t(16;16) and MLL rearrangements.
Fluorescence in situ hybridization analysis of nonproliferating (interphase) cells can be used to detect the common diagnostic and prognostic chromosome abnormalities observed in patients with AML.
Reference Values
An interpretive report will be provided.
Interpretation
A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal reference range for any given probe set.
The absence of an abnormal clone does not rule out the presence of an acute myeloid leukemia clone or another neoplastic disorder.
Day(s) Performed
Monday through Friday
Report Available
7 to 10 daysSpecimen Retention Time
4 weeksPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88271x2, 88275x1, 88291x1- FISH Probe, Analysis, Interpretation; 1 probe set
88271x2, 88275x1-FISH Probe, Analysis; each additional probe set (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
AMLMF | AML, Specified FISH | 102103-9 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
614204 | Result Summary | 50397-9 |
614205 | Interpretation | 69965-2 |
614206 | Result Table | 93356-4 |
614207 | Result | 62356-1 |
GC097 | Reason for Referral | 42349-1 |
GC098 | Probes Requested | 78040-3 |
GC099 | Specimen | 31208-2 |
614208 | Source | 31208-2 |
614209 | Method | 85069-3 |
614210 | Additional Information | 48767-8 |
614211 | Disclaimer | 62364-5 |
614212 | Released By | 18771-6 |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AMLMB | Probe, Each Additional (AMLMF) | No, (Bill Only) | No |
Forms
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.